258 related articles for article (PubMed ID: 19598262)
41. X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.
Miyamoto M; Takano M; Iwaya K; Shinomiya N; Kato M; Aoyama T; Sasaki N; Goto T; Suzuki A; Hitrata J; Furuya K
Br J Cancer; 2014 Jun; 110(12):2881-6. PubMed ID: 24853184
[TBL] [Abstract][Full Text] [Related]
42. Expression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcome.
Zimmermann U; Woenckhaus C; Teller S; Venz S; Langheinrich M; Protzel C; Maile S; Junker H; Giebel J
Histol Histopathol; 2007 May; 22(5):527-34. PubMed ID: 17330807
[TBL] [Abstract][Full Text] [Related]
43. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
44. Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Esposito F; Cecere SC; Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Scalone S; Rabaiotti E; Salutari V; Cormio G; Canuto EM; Greggi S; Savarese A; Marinaccio M; Scollo P; Santeufemia DA; Sacco C; Facchini G; Pignata S
Oncology; 2014; 86(5-6):351-8. PubMed ID: 24942520
[TBL] [Abstract][Full Text] [Related]
45. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
[TBL] [Abstract][Full Text] [Related]
46. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.
Wang-Johanning F; Liu J; Rycaj K; Huang M; Tsai K; Rosen DG; Chen DT; Lu DW; Barnhart KF; Johanning GL
Int J Cancer; 2007 Jan; 120(1):81-90. PubMed ID: 17013901
[TBL] [Abstract][Full Text] [Related]
47. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
[TBL] [Abstract][Full Text] [Related]
48. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
[TBL] [Abstract][Full Text] [Related]
49. Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma.
Tsubamoto H; Sonoda T; Yamasaki M; Inoue K
Anticancer Res; 2014 Apr; 34(4):2007-14. PubMed ID: 24692739
[TBL] [Abstract][Full Text] [Related]
50. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.
Itamochi H; Yoshida T; Walker CL; Bartholomeusz C; Aoki D; Ishihara H; Suzuki N; Kigawa J; Terakawa N; Ueno NT
Gynecol Oncol; 2011 Sep; 122(3):641-7. PubMed ID: 21652059
[TBL] [Abstract][Full Text] [Related]
51. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Mabuchi S; Sugiyama T; Kimura T
J Gynecol Oncol; 2016 May; 27(3):e31. PubMed ID: 27029752
[TBL] [Abstract][Full Text] [Related]
52. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Takano M; Tsuda H; Sugiyama T
J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
[TBL] [Abstract][Full Text] [Related]
53. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
54. p53 protein aggregation promotes platinum resistance in ovarian cancer.
Yang-Hartwich Y; Soteras MG; Lin ZP; Holmberg J; Sumi N; Craveiro V; Liang M; Romanoff E; Bingham J; Garofalo F; Alvero A; Mor G
Oncogene; 2015 Jul; 34(27):3605-16. PubMed ID: 25263447
[TBL] [Abstract][Full Text] [Related]
55. Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer.
Liu J; Zheng M; Qi Y; Wang H; Liu M; Liu Q; Lin B
Int J Oncol; 2018 Oct; 53(4):1774-1786. PubMed ID: 30066907
[TBL] [Abstract][Full Text] [Related]
56. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.
Park JT; Chen X; Tropè CG; Davidson B; Shih IeM; Wang TL
Am J Pathol; 2010 Sep; 177(3):1087-94. PubMed ID: 20671266
[TBL] [Abstract][Full Text] [Related]
57. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
58. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
Oishi T; Itamochi H; Kigawa J; Kanamori Y; Shimada M; Takahashi M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(5):1040-6. PubMed ID: 17433067
[TBL] [Abstract][Full Text] [Related]
59. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.
Jinawath N; Vasoontara C; Jinawath A; Fang X; Zhao K; Yap KL; Guo T; Lee CS; Wang W; Balgley BM; Davidson B; Wang TL; Shih IeM
PLoS One; 2010 Jun; 5(6):e11198. PubMed ID: 20585448
[TBL] [Abstract][Full Text] [Related]
60. HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
Lopes-Coelho F; Gouveia-Fernandes S; Gonçalves LG; Nunes C; Faustino I; Silva F; Félix A; Pereira SA; Serpa J
Tumour Biol; 2016 Apr; 37(4):4813-29. PubMed ID: 26520442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
